Hematocrit Control, Symptom Burden, and Time Toxicity Among Phlebotomy-Treated Patients With Polycythemia Vera in the United States (SOHO 2026) - Sep 1, 2026 - Abstract #MPN-718; Location: LEVEL 3, HALL B3; "At survey, PHL+cyto patients were receiving hydroxyurea (64%), ruxolitinib (22%), ropeginterferon alfa-2b (10%), or hydroxyurea plus ruxolitinib combination (4%). In this real-world US cohort, hematocrit control was poor, and symptom burden persisted among phlebotomy-treated patients, including those receiving cytoreductive therapy. Patient-reported mild fatigue and time toxicity indicated a multifactorial burden for phlebotomy-treated patients, with patients losing 3–4 hours of their day per phlebotomy. These findings highlight a clear unmet need for therapies that improve hematocrit and symptom control while reducing time burden."
Clinical • Oncology • Polycythemia Vera
|
|
Lindsay Rein MD 1; Angela Fan 2; Chloe Hammond 3; Alicia Cerretani 2; Amber Simpson 3; Katie Lewis 3; Luis Hernandez 2
|